Nuzenio

Pembrolizumab

Pembrolizumab news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 16 latest news signals 10 publisher sources 100/100 entity strength

Latest news

BI-1808 Receives FDA Fast Track Designation in Ovarian Cancer - Targeted OncologyTargeted Oncology · Fri, 07 Aug 2026 20:14:04 GMTFDA Grants Fast Track Designation to BioInvent's BI-1808 for Ovarian Cancer - BioPharm InternationalBioPharm International · Fri, 07 Aug 2026 18:25:09 GMTElizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab - Urology TimesUrology Times · Fri, 07 Aug 2026 17:34:09 GMTBioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data - allsci.comallsci.com · Fri, 07 Aug 2026 16:28:01 GMTUnpacking Subgroup Data With First-Line Ipatasertib Plus Pembrolizumab in HNSCC - onclive.comonclive.com · Thu, 06 Aug 2026 22:53:51 GMTDr Thomas on the Safety Profile of Frontline Ipatasertib Plus Pembrolizumab in HNSCC - onclive.comonclive.com · Thu, 06 Aug 2026 21:37:16 GMTFDA Clears Trodelvy as First-Line Therapy for TNBC - Clinical Oncology NewsClinical Oncology News · Thu, 06 Aug 2026 19:42:10 GMTDevelopers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer - CancerNetworkCancerNetwork · Thu, 06 Aug 2026 16:04:44 GMT

Timeline

Fri, 07 Aug 2026 20:14:04 GMTBI-1808 Receives FDA Fast Track Designation in Ovarian Cancer - Targeted Oncology
Fri, 07 Aug 2026 18:25:09 GMTFDA Grants Fast Track Designation to BioInvent's BI-1808 for Ovarian Cancer - BioPharm International
Fri, 07 Aug 2026 17:34:09 GMTElizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab - Urology Times
Fri, 07 Aug 2026 16:28:01 GMTBioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data - allsci.com
Thu, 06 Aug 2026 22:53:51 GMTUnpacking Subgroup Data With First-Line Ipatasertib Plus Pembrolizumab in HNSCC - onclive.com
Thu, 06 Aug 2026 21:37:16 GMTDr Thomas on the Safety Profile of Frontline Ipatasertib Plus Pembrolizumab in HNSCC - onclive.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Pembrolizumab.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

10 distinct publisher/source names are currently connected to this entity page.